Exact Mass: 512.0731

Exact Mass Matches: 512.0731

Found 11 metabolites which its exact mass value is equals to given mass value 512.0731, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

   

2-amino-6-(4-chlorophenyl)sulfanyl-4-[1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-5-yl]pyridine-3,5-dicarbonitrile

2-amino-6-(4-chlorophenyl)sulfanyl-4-[1-[(2R,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-5-yl]pyridine-3,5-dicarbonitrile

C22H17ClN6O5S (512.067)


   

5-O-{[(1S)-1-carboxylatoethoxy]phosphinato}-1-deoxy-1-(8-hydroxy-2,4-dioxo-2H-pyrimido[4,5-b]quinolin-3-id-10(4H)-yl)-D-ribitol

5-O-{[(1S)-1-carboxylatoethoxy]phosphinato}-1-deoxy-1-(8-hydroxy-2,4-dioxo-2H-pyrimido[4,5-b]quinolin-3-id-10(4H)-yl)-D-ribitol

C19H19N3O12P-3 (512.0706)


   

N-[(6-methoxy-2-oxo-1H-quinolin-3-yl)methyl]-5-methyl-N-(thiophen-2-ylmethyl)-2,1,3-benzothiadiazole-4-sulfonamide

N-[(6-methoxy-2-oxo-1H-quinolin-3-yl)methyl]-5-methyl-N-(thiophen-2-ylmethyl)-2,1,3-benzothiadiazole-4-sulfonamide

C23H20N4O4S3 (512.0647)


   

ustilaginoidin A dianion

ustilaginoidin A dianion

C28H16O10-2 (512.0743)


   

(4-{(E)-[5-(4-chlorophenyl)-6-(ethoxycarbonyl)-7-methyl-3-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidin-2(3H)-ylidene]methyl}phenoxy)acetic acid

(4-{(E)-[5-(4-chlorophenyl)-6-(ethoxycarbonyl)-7-methyl-3-oxo-5H-[1,3]thiazolo[3,2-a]pyrimidin-2(3H)-ylidene]methyl}phenoxy)acetic acid

C25H21ClN2O6S (512.0809)


   

ustilaginoidin A(2-)

ustilaginoidin A(2-)

C28H16O10 (512.0743)


A phenolate anion that is the conjugate base of ustilaginoidin A, obtained by deprotonation of the two hydroxy groups at positions 5 and 5. It is the major microspecies at pH 7.3.

   

GSK-25

GSK-25

C24H16Cl2F2N6O (512.0731)


GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC50=7 nM). GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC50=398 nM, p70S6K: IC50=1 μM). GSK-25 inhibits P450 profile (IC50s of 2.5, 5.2, 2.5 μM for CYP2C9, CYP2D6, CYP3A4, respectively)[1].

   

(1s,2s,3r,11r,14s)-2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione

(1s,2s,3r,11r,14s)-2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione

C23H20N4O4S3 (512.0647)


   

2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione

2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione

C23H20N4O4S3 (512.0647)


   

(1s,2s,3r,11r,14r)-2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione

(1s,2s,3r,11r,14r)-2-hydroxy-14-(hydroxymethyl)-3-(1h-indol-3-yl)-19-methyl-15,16,17-trithia-10,12,19-triazapentacyclo[12.3.2.0¹,¹².0³,¹¹.0⁴,⁹]nonadeca-4,6,8-triene-13,18-dione

C23H20N4O4S3 (512.0647)